FDA has granted St. Jude Medical Inc. an investigational device exemption for the EnligHTN IV trial, the first U.S. trial using the EnligHTN multielectrode renal denervation system, the company announced June 4. EnligHTN IV is the pivotal U.S. trial that will be the basis for an eventual FDA application for the EnligHTN renal denervation system for treating drug-resistant hypertension. (See Also see "St. Jude Plans Trial To Study Renal Denervation Outcomes" - Medtech Insight, 25 February, 2013..)
The randomized, single-blind study is planned for 590 patients with blood pressure of at least 160 mmHg who are taking three or more anti-hypertensive medications. About 80 North American centers...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?